Chai et al. performed an analysis of genomic and clinical data from 631 GBM patients in The Cancer Genome Atlas (TCGA) and discovered that the deletion of MPC1 is correlated with a poorer prognosis and resistance to temozolomide(TMZ) in GBM [49,50]. Here, MPC1 is linked to glioblastoma.